Protocols and planning key to avoiding warning letters; FDA

By Nick Taylor

- Last updated on GMT

Better designed protocols and early identification of risks can improve trial quality and help avoid warning letters, said the FDA.

In 2010, 95 per cent of US Food and Drug Administration (FDA) warning letters were related to the protocol. By designing a good protocol, identifying the goal of the trial, the risks involved, and sticking to the plan throughout the study, many common problems can be avoided.

Many clinical trial failures occur because people fail to see the big picture and primary objective of the study, David Lepay, senior advisor for clinical science, office of the commissioner, FDA, told an audience at DIA 2011.

It is impossible for a single clinical trial to answer every question so “prospective prioritisation​” should be performed to identify the primary objective well before the study runs into problems.

Lepay listed 11 other categories, in addition to prioritisation, that must be considered to ensure a clinical trial will be effective. For example, Lepay emphasised the importance of documentation. “If it isn’t documented it didn’t happen​”, Lepay said.

The organisation of documents and the site in general are also important. A well organised site and documentation system gives an FDA inspector a good first impression and starts the visit in a positive way.

Thoughtful automation

The rise of eClinical systems should, in theory, simplify some record keeping processes, but it also creates its own problems. It is important sites consider what controls are needed and that their processes meet requirements for the maintenance of accurate records.

Providing sites adopt a policy of “thoughtful automation​” though there is the potential for technology to improve trial quality. “The FDA very much encourages automation in clinical trials​”, said Lepay.

In the presentation Lepay listed 12 aspects to avoiding warning letters. These are: prioritisation; standardisation; protection; education; supervision; communication; organisation; documentation; thoughtful automation; correction and prevention; randomisation; and globalisation.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us

Products

View more

Webinars